|what happened to these guys? I was an||mrzm||10/29/15 11:26 PM|
|APSN revoked:||Renee||10/01/14 9:33 AM|
|APSN SEC Suspension:||Renee||06/17/14 9:37 AM|
|Hearing that Eli Lilly and APSN are on||pipejaws||03/17/14 7:18 PM|
|WHere is this stock going and what caused||pipejaws||01/16/14 8:58 AM|
|APSN is looking great at this level||kranthikumar||12/02/13 9:57 AM|
|Expedition 3 trial, paid for by Eli Lilly,||scotty12||10/14/13 3:13 AM|
|Look above and you'll see that Pfizer and||scotty12||09/14/13 12:02 AM|
|It's gonna be a few years before this||scotty12||12/19/12 3:54 AM|
|It turns out that J&J, along with Pfizer,||scotty12||11/24/12 12:59 PM|
|Eli Lilly and Applied Neurosolutions have an agreement||scotty12||11/09/12 5:32 PM|
|Trials for Alzheimer’s Drug Halted After Poor Results By||scotty12||11/09/12 5:14 PM|
|Eli Lilly Might Have an Alzheimer’s Cure LLY stock||scotty12||11/09/12 5:08 PM|
|been gettin some volume herepast few days.. somethings||Caerus||12/29/11 4:37 PM|
|What makes you say Pfizer is helping out?||monkeyman67||08/16/11 3:29 PM|
|It looks like Pfizer is also getting in||scotty12||07/18/11 2:18 PM|
|Well I sold back when they said they||roscoe48||06/17/10 8:29 AM|
|By the time they announce anything I'm going||roscoe48||05/05/10 2:58 PM|
|All it's going to take is a lot||roscoe48||04/26/10 10:00 AM|
|Tick Tock||roscoe48||03/24/10 11:02 AM|
|I wonder if people in the know are||roscoe48||01/13/10 1:44 PM|
|Nice. I am going to hold on||monkeyman67||12/23/09 11:05 AM|
|News came out today:||nitr05||12/23/09 1:58 AM|
|Hey Mortimor this might actually work out.||monkeyman67||12/22/09 11:47 AM|
|UPDATE!! I haven't spoken to management but I'm||roscoe48||12/17/09 9:17 AM|
|Applied NeuroSolutions Announces Renewal of Alzheimer’s Disease Drug||roscoe48||12/08/09 6:02 PM|
|I know what you mean. It is not||roscoe48||12/08/09 2:12 PM|
|We're back Mortimer.||monkeyman67||12/08/09 9:43 AM|
|Being a Mod. here is like being the||roscoe48||11/19/09 9:05 AM|
|Yes-sir-ree any minute now!||roscoe48||11/05/09 11:41 AM|
|NEWS!! I told you someone was working there!||roscoe48||10/09/09 8:32 AM|
|Any minute now!||roscoe48||10/01/09 9:13 AM|
|Excitement is growing! This thing is starting to||roscoe48||09/18/09 1:48 PM|
|Man a small float makes for some big moves!||roscoe48||09/14/09 11:18 AM|
|every time someone buys or sells this it||roscoe48||09/11/09 12:20 PM|
|I told you so!!||roscoe48||07/23/09 6:27 PM|
|Yeah I saw that. But they are reducing||roscoe48||06/25/09 9:03 AM|
|On June 5, 2009, the Registrant filed a||Kurupt||06/24/09 1:41 PM|
|Yeah this baby is going to take off||roscoe48||06/24/09 10:37 AM|
|News out today as well. This is||nohogs||07/28/08 10:09 AM|
|BottomBuster Alert DD Post on APNS.OB (.06) Extremely||$heff||07/28/08 12:06 AM|
|BS on there chart here today. Someone||nohogs||07/26/08 1:57 AM|
|held above the 50 day. Next volume surge||was sheepdog||07/23/08 8:02 AM|
|This is looking very nice.||nohogs||07/21/08 6:46 PM|
|The run is on||was sheepdog||07/21/08 6:42 PM|
|Big close here!!! .08! :-) nice volume too.||Bull Trader||07/21/08 4:43 PM|
|blocked? wtf? i dont know why. must be||Bull Trader||07/21/08 1:06 PM|
|i would reply to your PM but you||Stock Stallion||07/21/08 1:03 PM|
|sleeper stock.||Bull Trader||07/20/08 1:09 AM|
|Yep. I think that by quarter 4 this||nohogs||07/18/08 7:20 PM|
Applied NeuroSolutions, Inc. (APNS) is a development stage biopharmaceutical company focused on diagnostics and therapeutics for the treatment of Alzheimer’s Disease (AD).
Applied NeuroSolutions’ has a long-term agreement with Albert Einstein College of Medicine (AECOM) that grants APNS the exclusive licensing rights to commercialize Dr. Peter Davies’ neurodegenerative disease related discoveries. The technologies are based on the presence of an abnormal form of a protein present in the brains and cerebrospinal fluid (CSF) of AD patients. A specific chemical change in this protein, known as tau, results in an abnormal protein called ptau-231 (tau protein phosphorylated on amino acid 231). The presence of the ptau-231 protein leads to the development of abnormal structures (paired helical filaments and neurofibrillary tangles – the hallmark of Alzheimer’s disease) that contribute to nerve cell death. The correlation between excess amounts of the ptau-231 protein and AD supports the development of diagnostic tests, in vitro drug discovery systems and therapeutics aimed at preventing the formation of this protein and the accompanying neuron-destroying structures. The Company’s technology originated from Dr. Peter Davies, the Judith and Burton P. Resnick Professor of Alzheimer’s Disease Research at the Albert Einstein College of Medicine, and APNS’ scientific founder.
AD Diagnostic Test
Increased amounts of the altered tau protein (ptau-231) in cerebrospinal fluid (CSF) distinguish AD patients from those with other forms of cognitive impairment, providing an early diagnostic test and a method for following disease progression. Applied NeuroSolutions has developed an antibody-based test measuring the protein in the CSF of AD patients and is working on a second-stage blood serum-based test that is expected to be easier to perform and less expensive.
Currently there are no approved diagnostic tests to detect AD and follow its progression. Confirmation of diagnosis is performed through a series of behavioral measurements and brain scans. Definitive diagnosis can be made only from examination of postmortem brain tissue samples. Applied NeuroSolutions’ test would provide a significant breakthrough in supporting definitive early diagnosis.
Alzheimer’s Drug Discovery Platforms
The Company is working on a therapeutic program developed by Dr. Peter Davies based on the common pathway leading to the development of abnormal, destructive brain structures characteristic of AD. This screen can be used to identify drugs that interfere with that pathway, thereby preventing disease development.
Mouse Model for AD
Dr. Davies and the Nathan Kline Institute (NKI) have developed a transgenic mouse model of AD that exhibits Alzheimer-like pathology including accumulation of the abnormal form of tau (p-tau 231) and extensive neuronal death. These mice can be used to test for candidate drugs. The Company and NKI intend to market these models and several drug development companies have expressed interest in them.
Agreements with Pfizer, Novartis
Several major pharmaceutical and biotechnology companies have utilized Applied NeuroSolutions tools and technology to enhance their efforts to develop more effective drugs for Alzheimer's. In January 2003, the Company announced a Research Agreement with Pfizer, Inc. In November 2003, the Company also announced a Research Agreement with Novartis Pharmaceuticals Corporation.
Basis of Research
All of the Company's products and research tools are based upon a distinctive view of the cause and progression of Alzheimer’s disease developed over the past 25 years by Dr. Peter Davies and his colleagues at the Albert Einstein College of Medicine, where Dr. Davies currently serves as the Burton P. and Judith Resnick Professor of Alzheimer's Disease Research.
Applied NeuroSolutions was created from a reverse merger of Molecular Geriatrics Corporation into the public company Hemoxymed, Inc. on September 10, 2002. The management team comes from Molecular Geriatrics and has worked together as a group since 1993. The Company changed its name to Applied NeuroSolutions in October 2003 to reflect its focus upon the diagnosis and treatment of AD. The Company’s stock currently trades on the Over-the-Counter Bulletin Board (OTCBB) under the symbol APNS.OB.
The company's address is 50 Lakeview Parkway, Suite 111, Vernon Hills, Illinois, 60061. The telephone number is 847-573-8000 and the fax number is
The Company’s management team and board of directors include experienced scientists from both academic and pharmaceutical settings as well as senior executives with considerable experience in the development, management and commercialization of biotech and pharmaceutical products. Dr Peter Davies, the Company’s founding scientist is world renowned as an Alzheimer’s disease researcher.The Directors, executive officers, and certain key scientists and advisors of the Company are as follows:
|Ellen R. Hoffing||Chairman of the Board of Directors, President and Chief Executive Officer|
|Robert S. Vaters||Director|
|Jay B. Langner||Director|
|Alan L. Heller||Director|
|David C. Tiemeier, Ph.D.||Director|
|Peter Davies, Ph.D.||Founding Scientist|
|David Ellison, CPA||Chief Financial Officer & Corporate Secretary|
|John F. DeBernardis, Ph.D.||Chief Scientific Officer|
For Further Information, Contact:
|Ellen Hoffing, President and CEO||Applied NeuroSolutions, Inc.|
|Mailing Address:||50 Lakeview Pkwy, Suite 111 |
Vernon Hills, IL 60061
|David Ellison, CFO||Applied NeuroSolutions, Inc.|
|Mailing Address:||50 Lakeview Pkwy, Suite 111 |
Vernon Hills, IL 60061
Alzheimer’s disease (AD) is an intractable, chronic and progressively incapacitating disease characterized by the degeneration and death of several types of neurons in certain regions of the brain. Patients affected by the disease initially suffer loss of memory, then a decline of intellectual abilities severe enough to interfere with work and activities of daily living, followed by severe dementia and, finally, death. This illness, currently affecting an estimated 4.5 million people in the United States, and approximately ten million people worldwide, is a leading cause of death behind cardiovascular disease and cancer. While the disease is most common in the elderly, affecting nearly 10% of people age 65 and older and up to 50% of people age 85 and older, it has been diagnosed in patients in their 40’s and 50’s.*
Alzheimer’s disease was first described in 1907 by Dr. Alois Alzheimer, a German psychiatrist who discovered large numbers of unusual microscopic deposits in the brain of a demented patient upon autopsy. These deposits, called amyloid plaques and neurofibrillary tangles, are highly insoluble protein aggregates that form in the brains of AD patients in particular regions, including those involved with memory and cognition. Generally, amyloid plaque is deposited on the surface of neurons, whereas neurofibrillary tangles are formed within neurons. The plaques and tangles are associated with degeneration and loss of neurons. The actual loss of neurons, as well as the impaired function of surviving neurons, is generally believed to be the key neuropathological contributors to the memory loss and dementia that characterizes Alzheimer’s disease.
Applied NeuroSolutions’s core technology in the AD field is based on the work of its founding scientist Dr. Peter Davies and his colleagues at the Albert Einstein College of Medicine. Much of Dr. Davies’ AD research has been involved within an abnormal form of a protein called tau that normally serves to stabilize microtubules, the transit system in nerve cells that directs molecules to their destinations. Excessive phosphorylation of tau prevents it from stabilizing microtubules. This internal neuronal damage leads to the development of the paired helical filaments and neurofibrillary tangles, which are contributing factors to the eventual death of the neurons related to Alzheimer’s disease, and is one of the hallmark pathologies associated with AD. There is a high correlation among the presence of neurofibrillary tangles and cognitive decline in AD.
* Alzheimer’s Association, February 2006
Alzheimer’s disease, at present, can be conclusively diagnosed only by histological examination of the brain by biopsy or autopsy. The diagnosis of patients suspected of having AD is therefore typically made through a process of elimination, by conducting neurological and psychiatric examinations, extensive laboratory tests and a brain scan to rule out other conditions (such as stroke, brain tumor, or depression) with similar symptoms. The definitive AD predictive accuracy of such exams is generally in the range of 75-80%. Costs to patients for such testing currently runs anywhere from $1,000 - $4,000. A simple, predictive, accurate and cost effective diagnostic assay would therefore meet a tremendous medical need.
Applied NeuroSolutions has completed the development of a diagnostic assay utilizing cerebrospinal fluid (CSF). To date, the Company has completed numerous studies comprising in excess of 2,500 CSF samples utilizing this assay. These studies were designed to test the assay’s ability to differentiate patients diagnosed with AD from patients diagnosed with other forms of dementia and relevant neurological diseases, including major depression, as well as healthy controls. These studies have shown the ability of the assay to correctly identify the patients diagnosed with AD with an overall sensitivity and specificity in the 85% to 95% range. The studies have been published in peer reviewed scientific journals such as Neuroscience Letters, Archives of Neurology, Annals of Neurology, Archives of General Psychiatry, Journal of Internal Medicine, Neurobiology of Aging, Neurology, and American Journal of Psychiatry.
These data suggest that the phosphotau may represent an excellent biochemical marker for AD. It detects a characteristic feature of pathophysiology, may allow one to track disease progression and accurately discriminates between AD patients and neurological controls. Several pharmaceutical companies have utilized the Company’s CSF phosphotau assay as a biomarker in the clinical development of therapeutics to treat AD.
The Company’s long-range goal is to discover and develop novel therapeutics to treat AD. Work is being conducted utilizing an in-vitro screen Dr. Davies has developed that could lead to the discovery of a therapeutic to stop the progression of Alzheimer’s disease. The basis for this screen is the discovery of a common pathway that leads to the development of both the neurofibrillary tangles and amyloid plaques.
The market potential for a drug to effectively treat Alzheimer’s disease is extremely large. Currently there are only five drugs approved in the U.S. to treat AD. Four of these drugs are cholinesterase inhibitors and one is an NMDA receptor antagonist. These drugs have limited beneficial effects in treating symptoms associated with AD and are not able to arrest the progression of the disease.
Transgenic Mice Model
To date, no accepted animal model for AD has been developed. However, recently Dr. Peter Davies, through collaboration with a researcher at Nathan Klein Institute (“NKI”), has produced a transgenic mouse that develops neurofibrillary tangles, one of the two hallmark pathologies of Alzheimer’s disease. The pathology in these mice is Alzheimer-like, with hyperphosphorylated tau accumulating in cell bodies and dendrites leading to the production of neurofibrillary tangles. In addition, these transgenic mice have exhibited extensive neuronal death, which accompanies the tau pathology. These new transgenic mice could be used for testing the efficacy of therapeutic compounds. Several pharmaceutical and biotechnology companies have expressed interest in acquiring access to these transgenic mice for testing their therapeutics. The Company and NKI are currently marketing these mice to researchers.
|% Held by Insiders:||30.19%|
|% Held by Institutions:||1.40%|
Total Cash (mrq): 2.56M Total Cash Per Share (mrq): 0.02 Total Debt (mrq): 0 Total Debt/Equity (mrq): N/A Current Ratio (mrq): 3.042
(2 Year Chart)